Here are three observations:
1. Pushing the market forward are innovative technology advancements, demand for minimally invasive spine surgery and newly developed spine treatments.
2. The market will need to overcome unfavorable reimbursement policy, high costs and lack of professional expertise during the forecast period.
3. Top market players include DePuy Synthes, Precision Spine, Medtronic and Stryker.
More articles on biologics:
SpinalCyte receives new patent for cartilage repair: 3 insights
Biologics in spine surgery holds great promise — Dr. Choll Kim shares insight into new field
InVivo Therapeutics concludes INSPIRE study: 5 things to know
